Education
About Us
Working with TipRanks
Follow Us
WPD Pharmaceuticals (TSE:WBIO)
:WBIO
WBIO Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.07 - C$0.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$324.76K
Enterprise ValueN/A
Total Cash (Recent Filing)$9.34K
Total Debt (Recent Filing)$390.88K
Price to Earnings (P/E)―
Beta-0.09
Next Earnings
Jul 31, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,639,485
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
WPD Pharmaceuticals News
WBIO FAQ
What was WPD Pharmaceuticals’s price range in the past 12 months?
WPD Pharmaceuticals lowest stock price was C$0.07 and its highest was C$0.50 in the past 12 months.
What is WPD Pharmaceuticals’s market cap?
WPD Pharmaceuticals’s market cap is $324.76K.
When is WPD Pharmaceuticals’s upcoming earnings report date?
WPD Pharmaceuticals’s upcoming earnings report date is Jul 31, 2025 which is 61 days ago.
How were WPD Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is WPD Pharmaceuticals overvalued?
According to Wall Street analysts WPD Pharmaceuticals’s price is currently Overvalued.
Does WPD Pharmaceuticals pay dividends?
WPD Pharmaceuticals does not currently pay dividends.
What is WPD Pharmaceuticals’s EPS estimate?
WPD Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does WPD Pharmaceuticals have?
WPD Pharmaceuticals has 4,639,485 shares outstanding.
What happened to WPD Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of WPD Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:WBIO
Company Description
WPD Pharmaceuticals
WPD Pharmaceuticals Inc. engages in the research and development of medicinal products in the fields of oncology and infectious diseases. Its drug development pipeline includes WPD101 to treat brain cancers, including glioblastoma that is in the pre-clinical trial; WPD102 to treat Uval Melanoma, which is in the pre-clinical trial; Berubicin for the treatment of glioblastoma that us in phase 1 clinical trial; and WP1066 to treat central nervous system tumors, pancreatic cancer, and ocular tumors, which is in phase 1 clinical trial. The company's drug development pipeline also includes WP1732 for the treatment of pancreatic cancer; WP1220 to treat cutaneous T-cell lymphoma; WPD103 for the treatment of glioblastoma multiforme that is in the pre-clinical trial; and Annamycin to treat acute myeloid leukemia (AML) and metastasis to lungs, which is in Phase I/II clinical trials in AML. WPD Pharmaceuticals Inc. is headquartered in Vancouver, Canada.
Technical Analysis
Advanced Proteome Therapeutics
―
NanoSphere Health Sciences Inc
―
Wesana Health Holdings Inc
―
Biocure Technology Inc
―
Albert Labs International
―
Options Prices
Currently, No data available
---